--- title: "Milestone Pharmaceuticals (MIST) news: offering" url: "https://aibio.space/companies/milestone-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MIST offering news: Milestone Pharmaceuticals lifts Jefferies at-the-market program to up to $77,800,000. Milestone Pharmaceuticals Inc." --- MIST Milestone Pharmaceuticals Inc. NASDAQ · Canada # Milestone Pharmaceuticals (MIST) news MIST offering news Listings · 2026-10-28 ## [Milestone Pharmaceuticals falls below Nasdaq's $1.00 minimum bid rule](https://aibio.space/news/milestone-pharmaceuticals-falls-below-nasdaqs-1-00-minimum-bid-rule/) Milestone has until April 21, 2027 to close at $1.00 or more for 10 consecutive business days, after 30 consecutive business days below that level. ## Latest Milestone Pharmaceuticals news 1. 2025-03-18 Financings [Milestone Pharmaceuticals lifts Jefferies at-the-market program to up to $77,800,000](https://aibio.space/news/milestone-pharmaceuticals-lifts-jefferies-market-program-up-77-800-000/) Milestone amended its Jefferies sales agreement to allow up to $75,000,000 of new common shares, within a $77,800,000 total that includes about $2.8 million already sold. Jefferies can earn up to 3.0% commission, and the shares closed at $2.41 on March 17, 2025. ## Milestone Pharmaceuticals at a glance - **Ticker**: MIST - **Listing**: NASDAQ - **Country**: Canada - **Cash, Jun 30, 2026**: $170.6 million ### Related companies - [BetterLife Pharma](https://aibio.space/companies/betterlife-pharma/) CSE: BETR - [Arch Biopartners](https://aibio.space/companies/arch-biopartners/) TSXV: ARCH - [Telescope Innovations](https://aibio.space/companies/telescope-innovations/) CSE: TELI - [Nurexone Biologic](https://aibio.space/companies/nurexone-biologic/) TSXV: NRX - [Psyence Biomedical](https://aibio.space/companies/psyence-biomedical/) NASDAQ: PBM - [Manzo Pharmaceuticals](https://aibio.space/companies/manzo-pharmaceuticals/) OTC: MNZO - [NORTH BUD FARMS INC](https://aibio.space/companies/north-bud-farms/) OTC: NOBDF - [Apotex Health](https://aibio.space/companies/apotex-health/) TSX: APTX ### Also on NASDAQ - [Atossa Therapeutics](https://aibio.space/companies/atossa-therapeutics/) ATOS - [Artiva Biotherapeutics](https://aibio.space/companies/artiva-biotherapeutics/) ARTV - [United Therapeutics](https://aibio.space/companies/united-therapeutics/) UTHR - [Xenon Pharmaceuticals](https://aibio.space/companies/xenon-pharmaceuticals/) XENE - [Larimar Therapeutics](https://aibio.space/companies/larimar-therapeutics/) LRMR - [Evogene](https://aibio.space/companies/evogene/) EVGN ## Milestone Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$1.5 million](https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/) | [$0](https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/) | | Research and development | [$18.1 million](https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/) | [$14.4 million](https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/) | | Net income (loss) | [-$63.1 million](https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/) | [-$41.5 million](https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/) | | Cash from operations | [-$49.0 million](https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/) | [-$28.8 million](https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/) | | Cash and equivalents | [$73.0 million](https://www.sec.gov/Archives/edgar/data/1408443/000110465926094435/) | [$25.3 million](https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/) | | Short-term investments | [$32.9 million](https://www.sec.gov/Archives/edgar/data/1408443/000110465926094435/) | [$44.4 million](https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $169.7 million, plus short-term investments of $881,000, $170.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Milestone Pharmaceuticals Has Milestone Pharmaceuticals raised money recently? Our latest story on this, dated Mar 18, 2025: "Milestone Pharmaceuticals lifts Jefferies at-the-market program to up to $77,800,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/milestone-pharmaceuticals-lifts-jefferies-market-program-up-77-800-000/). What is the ticker symbol of Milestone Pharmaceuticals? Milestone Pharmaceuticals Inc. trades under the ticker MIST on NASDAQ. Where is Milestone Pharmaceuticals listed? Milestone Pharmaceuticals Inc. is listed on NASDAQ. What is the SEC CIK of Milestone Pharmaceuticals? The SEC Central Index Key (CIK) for Milestone Pharmaceuticals Inc. is 1408443. Its filings are on SEC EDGAR. How many shares does Milestone Pharmaceuticals have outstanding? 124,497,980 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Milestone Pharmaceuticals listed under? Our directory records Milestone Pharmaceuticals Inc. under Canada. What does Milestone Pharmaceuticals do? Our directory classifies Milestone Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Milestone Pharmaceuticals? The ISIN recorded for Milestone Pharmaceuticals Inc. is CA59935V1076. Does aibio.space cover Milestone Pharmaceuticals? aibio.space lists Milestone Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Milestone Pharmaceuticals incorporated? SEC records list its state or country of incorporation as A8. What was Milestone Pharmaceuticals's revenue last year? $1.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Milestone Pharmaceuticals profitable? Milestone Pharmaceuticals Inc. reported a net loss of $63.1 million for the fiscal year ended Dec 31, 2025, and used $49.0 million of cash in operations, per its annual report to the SEC. How much does Milestone Pharmaceuticals spend on research and development? $18.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Milestone Pharmaceuticals have? $170.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Milestone Pharmaceuticals (MIST) stock news? Our latest story on Milestone Pharmaceuticals, dated Oct 28, 2026: "Milestone Pharmaceuticals falls below Nasdaq's $1.00 minimum bid rule". Milestone has until April 21, 2027 to close at $1.00 or more for 10 consecutive business days, after 30 consecutive business days below that level. [Source](https://aibio.space/news/milestone-pharmaceuticals-falls-below-nasdaqs-1-00-minimum-bid-rule/). ## Investor discussion: Milestone Pharmaceuticals Members talk about Milestone Pharmaceuticals (MIST). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Milestone Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1408443/000110465926119669/tm2628459d1_8k.htm) 2. 2026-05-13 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1408443/000110465926060391/tm2614252-1_s3.htm) 3. 2025-03-18 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1408443/000110465925025055/tm259429d2_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MIST on TradingView](https://www.tradingview.com/symbols/NASDAQ-MIST/). ## SEC filings and registration - **SEC name**: Milestone Pharmaceuticals Inc. - **CIK**: 1408443 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: MIST (Nasdaq) - **State or country of incorporation**: A8 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, Quebec, Canada, H4M 2X6 - **Phone**: (514) 336-0444 - **Shares outstanding**: 124,497,980 as of 2026-08-12 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1408443/000110465926105052/tm2624766d1_8k.htm) filed 2026-09-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1408443/000110465926094466/tm2614433d1_8k.htm) filed 2026-08-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000110465926094435/mist-20260630x10q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/tm2617859d1_8k.htm) filed 2026-06-15 - [S-3](https://www.sec.gov/Archives/edgar/data/1408443/000110465926060391/tm2614252-1_s3.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/tm2614433d1_8k.htm) filed 2026-05-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000110465926059752/mist-20260331x10q.htm) filed 2026-05-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1408443/000110465926052880/tm2616218d1_def14a.htm) filed 2026-04-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001408443), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Milestone Pharmaceuticals Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MIST, recorded under Canada. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Milestone Pharmaceuticals Inc. - **Ticker**: MIST - **Listing**: NASDAQ - **Country or territory**: Canada - **Business scope**: Pharmaceuticals: Major - **ISIN**: CA59935V1076 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MIST/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/milestone-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Milestone Pharmaceuticals (MIST) news: offering", 2026-10-31, https://aibio.space/companies/milestone-pharmaceuticals/